Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Psoriatic arthritis
•
General Rheumatology
•
Dermatology
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Are there any concerns when combining apremilast with azathioprine?
Have you seen drug induced SCLE from IL-17 inhibitors?
